We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The feasibility of PETHEMA ALL-96 regimen on treatment of patients with acute lymphoid leukemia.
- Authors
Ashrafi, Farzaneh; Sadeghi, Alireza; Derakhshandeh, Ali; Oghab, Padideh
- Abstract
Background: Asparaginase-based treatment regimen for acute lymphocytic leukemia (ALL) is considered as feasible, but there is still a lack of data. In this study, considering the results of other regimen that were not optimum in previous studies. Here, we aimed to investigate the feasibility of PETHEMA ALL-96 treatment regimen. Materials and Methods: This is a retrospective feasibility study that was performed in 2019-2021 on 13 patients diagnosed with B-cell ALL. Patients were treated by PETHEMA ALL-96 regimen during induction, consolidation, reinduction, and maintenance phases. Patients were followed for 2 years after initiation of PETHEMA ALL-96 regimen for disease-free survival (DFS) and overall survival (OS) of all patients were evaluated after 2 years. Results: Data of 11 patients were analyzed. Within 28 days after treatments, all patients (100%) had no blasts in the bone marrow that was considered as complete remission (CR). The CR rate was 100% within 6 months and 12 months and 81.8% within 2 years after the treatments. Evaluation of OS, CR, and DFS regarding 6, 12, and 24 months showed 100% for all items after 6 and 12 months. After 24 months, the CR was 90.9%, the OS was 81.8% and the DFS was 90.9%. None of the patients died during the induction phase and during the 12 months study. No side effects were observed. Conclusion: The PETHEMA ALL-96 had high feasibility and survival rates with no side effects during the study course. It is believed that PETHEMA ALL-96 regimen has beneficial outcomes in young patients with ALL.
- Subjects
MITOXANTRONE; RETROSPECTIVE studies; IDARUBICIN; TREATMENT effectiveness; LYMPHOCYTIC leukemia; DESCRIPTIVE statistics; PROGRESSION-free survival; BONE marrow
- Publication
Journal of Research in Medical Sciences, 2023, Vol 28, Issue 4, p1
- ISSN
1735-1995
- Publication type
Article
- DOI
10.4103/jrms.jrms_4_22